Accuray Incorporated (ARAY)

Market Cap	35.42M -78.2%
Revenue (ttm)	428.57M -7.9%
Net Income	-46.13M
EPS	-0.39
Shares Out	118.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,353,172
Open	0.3130
Previous Close	0.3129
Day's Range	0.2821 - 0.3158
52-Week Range	0.2801 - 2.1000
Beta	1.43
Analysts	Buy
Price Target	2.68 (+800.24%)
Earnings Date	May 6, 2026

About ARAY

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidne...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 8, 2007
• Employees: 990
• Stock Exchange: NASDAQ
• Ticker Symbol: ARAY
• Website: https://www.accuray.com

Financial Performance

In fiscal year 2025, Accuray's revenue was $458.51 million, an increase of 2.68% compared to the previous year's $446.55 million. Losses were -$1.59 million, -89.77% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for ARAY stock is "Buy." The 12-month stock price target is $2.68, which is an increase of 800.24% from the latest price.

Price Target

$2.68

(800.24% upside)

Analyst Consensus: Buy